Your Followed Topics

Top 8 u.s. securities and exchange commission News Today

#1
finance.yahoo.com
#1 out of 896.41%
business1h ago

Why This Fund Dumped $35 Million of UiPath Even as Revenue Grew 17%

https://finance.yahoo.com/markets/stocks/articles/why-fund-dumped-35-million-213000499.html
Finance.yahoo.com
  • Capital Impact Advisors reduced its UiPath stake by 2,753,724 shares in Q1, totaling about $35.07 million in value.
  • UiPath’s stock activity left the fund with 434,882 shares, worth about $4.83 million at quarter end.
  • The sale reduced UiPath to roughly 1.95% of the fund’s AUM as of March 31, 2026.
  • UiPath’s latest quarter showed 17% revenue growth to $418 million and higher ARR.
  • Capital Impact’s top holdings after the filing included Nvidia, Meta, and UiPath.
  • UiPath shares traded around $11.72, underperforming the S&P 500 over the past year.
  • The Motley Fool notes UiPath’s turnaround narrative remains intact despite the sale.
  • Capital Impact’s decision followed a broader trend of exiting positions in software names.
  • UiPath reported a strong cash position with $1.42 billion in cash, cash equivalents, and marketable securities.
  • UiPath’s platform focuses on RPA, AI-driven process discovery, and enterprise automation.
  • The Motley Fool provided a stock recommendation context, noting other stocks on its top 10 list.
Vote 0
0
#2
Moleculin Presents ASCO Data Showing No Detectable Cardiotoxicity with Annamycin at High Exposure
#2 out of 8
health1d ago

Moleculin Presents ASCO Data Showing No Detectable Cardiotoxicity with Annamycin at High Exposure

https://www.tradingview.com/news/tradingview:c549c4a9c7ed4:0-moleculin-presents-asco-data-showing-no-detectable-cardiotoxicity-with-annamycin-at-high-exposure/
Tradingview.com
  • Moleculin reports pooled ASCO data showing no detectable cardiotoxicity from Annamycin at high exposure.
  • In 90 patients, LVEF change was not significant (mean diff -0.12%).
  • No correlation found between cumulative Annamycin dose and LVEF changes.
  • Independent Cleveland Clinic review found no evidence of drug-induced cardiotoxicity.
  • Phase 1b/2 AML results show favorable responses reinforcing MIRACLE trial rationale.
  • The data come from ASCO presentations and SEC filings about Moleculin Biotech, Inc.
  • The summary is AI-generated and should be verified against the source.
  • Cumulative dose exposure reached a median of 660 mg/m² in the analysed cohort.
  • The ASCO data included 78 patients with paired LVEF measurements.
  • The study found no significant LVEF change despite high exposure, supporting safety signals.
Vote 0
0
#3
Live Oak Acquisition V schedules June 16 shareholder vote after S-4 declared effective
#3 out of 8
business1d ago

Live Oak Acquisition V schedules June 16 shareholder vote after S-4 declared effective

https://www.tradingview.com/news/tradingview:7d32006e41e05:0-live-oak-acquisition-v-schedules-june-16-shareholder-vote-after-s-4-declared-effective/
Tradingview.com
  • Live Oak Acquisition V says the SEC declared the S-4 effective and schedules a June 16, 2026 shareholder vote.
  • The vote will be conducted virtually for shareholders of record as of May 7, 2026.
  • Materials for the proposed business combination are on SEC.gov for review.
  • Closing is expected shortly after the meeting, subject to customary conditions.
Vote 0
0
#4
seekingalpha.com
#4 out of 8
crime1d ago

SEC charges Texas man in multimillion-dollar AI crypto asset fraud

https://seekingalpha.com/news/4598475-sec-charges-texas-man-in-multimillion-dollar-ai-crypto-asset-fraud
Seekingalpha.com
  • The SEC charged a Texas man in a multimillion-dollar fraud tied to AI and crypto assets.
  • Investigators say the scheme marketed crypto tokens and investment products with promised AI-driven returns.
  • Investors across the United States were reportedly misled about asset legitimacy and performance.
  • Funds allegedly paid to earlier investors and personal expenses were described as part of the scheme.
  • The complaint outlines how money flow was controlled to conceal the investments' true nature.
  • The SEC seeks disgorgement, interest, penalties, and injunctive relief to stop further harm.
  • The action underscores regulator focus on crypto assets and AI-enabled investments.
  • The case highlights the need for investor protection and clear disclosures in evolving markets.
  • Federal authorities pursue civil action to recover funds and halt the alleged scheme.
  • The SEC's complaint signals ongoing enforcement in AI and crypto investment spaces.
Vote 0
0
#5
Trump’s top Wall Street cop shoots down Biden-era climate rules for US firms
#5 out of 8
business1d ago

Trump’s top Wall Street cop shoots down Biden-era climate rules for US firms

https://nypost.com/2026/05/29/business/trumps-top-wall-street-cop-shoots-down-biden-era-climate-rules-for-us-firms/
Nypost.com
  • Trump ally SEC chair moves to repeal Biden-era climate disclosure rule for US firms.
  • Atkins argues the disclosure rules impose burdens and exceed authority.
  • Regulatory push aligns with Trump administration’s deregulation agenda.
  • Rule would have required reporting on climate risks and emissions if kept.
  • California already enforces its own climate disclosure law.
  • SEC remains independent of the White House while weighing public comments.
  • Policy repeal could be formalized within the next year.
  • The rule aimed to track emissions from customers and suppliers originally.
  • The climate rule was part of ESG-focused investment considerations.
Vote 0
0
#6
Anterix Stock Is Up 140%. Here's Why One Investor Just Bought $15.8 Million | The Motley Fool
#6 out of 8
business23h ago

Anterix Stock Is Up 140%. Here's Why One Investor Just Bought $15.8 Million | The Motley Fool

https://www.fool.com/coverage/filings/2026/05/29/anterix-stock-is-up-140-here-s-why-one-investor-just-bought-usd15-8-million/
Fool.com
  • Plustick Management disclosed a new stake in Anterix, acquiring 499,596 shares valued at about $15.81 million.
  • The quarter-end value of the stake reached about $19.08 million after price movements and more shares were added.
  • Plustick Management’s new stake accounts for about 9.21% of its reportable U.S. equity assets as of March 31, 2026.
  • Anterix trades around $64.02, up about 140% over the past year and outperforming the S&P 500's 28% gain.
  • The report notes momentum from regulatory and commercial developments for Anterix's private broadband strategy.
  • The FCC expanded the 900 MHz broadband allocation from 6 MHz to 10 MHz, supporting Anterix's growth potential.
  • Anterix ended December with nearly $30 million in cash and no debt.
  • Analysts note a growing revenue pipeline tied to private broadband deployments for utilities.
  • The article features Plustick Management's position as a potential catalyst for Anterix's stock trajectory.
  • Anterix’s focus is on private broadband networks using 900 MHz spectrum for utilities and critical infrastructure.
Vote 0
0
#7
National Pension Service Increases Stock Position in O'Reilly Automotive, Inc. $ORLY
#7 out of 8
business13h ago

National Pension Service Increases Stock Position in O'Reilly Automotive, Inc. $ORLY

https://www.marketbeat.com/instant-alerts/filing-national-pension-service-increases-stock-position-in-oreilly-automotive-inc-orly-2026-05-30/
Marketbeat.com
  • National Pension Service raised its ORLY stake by 1.8% in the fourth quarter, bringing holdings to 2.13 million shares worth about $194.1 million.
  • Insiders, including SVPs Hopper and Dumas, sold a combined 104,530 ORLY shares last quarter, signaling insider dispositions.
  • Analysts maintain a Moderate Buy on ORLY with an average price target of $112.25 as the stock nears its 52-week low.
  • MarketBeat notes a broad institutional ownership with 85% of ORLY stock held by institutions.
  • O'Reilly Automotive reported recent quarter results with $0.72 EPS, topping estimates by $0.03.
  • UBS, RBC, Truist and other analysts recently issued higher targets or ratings on ORLY, supporting bullish sentiment.
  • MarketBeat highlights the stock’s 52-week performance as a context for current activity.
  • The alert is part of MarketBeat's broader coverage of 13F filings and institutional moves.
  • MarketBeat reports additional insider activity and competitor moves to give a full context of ORLY's current environment.
  • MarketBeat compiles data from 13F filings to present a consensus view on ORLY's outlook.
  • MarketBeat offers readers access to additional stock ideas and research tools.
Vote 0
0
#8
As SpaceX IPO nears, traders think it's a near-certainty Musk becomes the first trillionaire
#8 out of 8
business12h ago

As SpaceX IPO nears, traders think it's a near-certainty Musk becomes the first trillionaire

https://www.cnbc.com/2026/05/29/as-spacex-ipo-nears-traders-think-musk-will-be-the-first-trillionaire.html
Cnbc.com
  • Traders assign over 90% odds that Elon Musk becomes the world's first trillionaire before 2027, based on SpaceX IPO momentum.
  • Analysts see similar odds for hitting the trillionaire milestone before 2028, suggesting continued momentum.
  • Musk denied a Bloomberg report that SpaceX valuation was lowered, reinforcing optimism for a blockbuster IPO.
  • SpaceX is expected to debut on Nasdaq early next month as confidential SEC filings were made in April.
  • Analysts consider a SpaceX-Tesla merger could help Musk consolidate control over the AI ecosystem.
  • The report highlights that SpaceX's IPO remains dominant against other historic IPO deals.
  • CNBC and Kalshi are cited as sources tracking market odds and confirming the IPO timeline.
  • The piece notes that SpaceX's valuation discussions are part of broader bets on AI ecosystem leadership.
  • The report mentions Musk's ownership ambitions as a driver behind potential corporate moves.
  • SpaceX filed confidentially with the SEC in April, signaling early regulatory steps ahead of the IPO.
Vote 0
0

Explore Your Interests

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement